Vaccines and compositions against
View Patent ↗Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromized patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae . The antigens may be used therapeutically or prophylactically.
1. A method for treating a subject suffering from or susceptible to Streptococcus pneumoniae infection, comprising administering an effective amount of a vaccine formulation comprising:
(1) a first isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 265; and
(2) a second isolated polypeptide comprising:
(a) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 10, or
(b) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:6.
2. The method of claim 1 , wherein the method inhibits infection by S. pneumoniae in an uninfected subject.
3. The method of claim 1 , wherein the method inhibits S. pneumoniae colonization in a subject.
4. The method of claim 1 , wherein the method inhibits S. pneumoniae symptoms.
5. The method of claim 1 , wherein the method inhibits S. pneumoniae -induced sepsis.
6. The method of claim 1 , wherein the method treats a subject with one dose.
7. The method of claim 1 , wherein the method treats a subject within three doses.
8. The method of claim 1 , wherein the subject is a human.
9. The method of claim 1 , wherein:
the second isolated polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 10, and the vaccine formulation further comprises a third isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:6.
10. The method of claim 1 , wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO:265.
11. The method of claim 1 , wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:10.
12. The method of claim 1 , wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:6.
13. The method of claim 1 , wherein at least one of the first and second polypeptides are lipidated.
14. The method of claim 9 , wherein at least one of the first, second, and third polypeptides are lipidated.
15. A method comprising:
administering a pharmaceutical composition to a subject, wherein the pharmaceutical composition includes:
(1) a first isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 265; and
(2) a second isolated polypeptide comprising:
(a) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 10, or
(b) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 6.
16. The method of claim 15 , wherein the subject is a human.
17. The method of claim 15 , wherein at least one of the first and second polypeptides are lipidated.
18. The method of claim 15 , wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO:265.
19. The method of claim 15 , wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:10.
20. The method of claim 15 , wherein the second isolated polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 10, and the pharmaceutical composition further comprises a third isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:6.